Fingolimod/natalizumabTumefactive multiple sclerosis relapse after natalizumab withdrawal: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2013年 / 1433卷 / 1期
关键词：
D O I：
10.1007/s40278-013-0380-6
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：22 / 22
相关论文
共 50 条
  • [31] Fingolimod/natalizumab interactionEosinophilia: case report
    Reactions Weekly, 2017, 1643 (1) : 122 - 122
  • [32] Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
    Bigaut, Kevin
    Kremer, Laurent
    Fabacher, Thibaut
    Ahle, Guido
    Goudot, Mathilde
    Fleury, Marie
    Gaultier, Claude
    Courtois, Sylvie
    Collongues, Nicolas
    de Seze, Jerome
    JOURNAL OF NEUROLOGY, 2022, 269 (06) : 3295 - 3300
  • [33] Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod
    Jander, Sebastian
    Turowski, Bernd
    Kieseier, Bernd C.
    Hartung, Hans-Peter
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (11) : 1650 - 1652
  • [34] Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
    Kévin Bigaut
    Laurent Kremer
    Thibaut Fabacher
    Guido Ahle
    Mathilde Goudot
    Marie Fleury
    Claude Gaultier
    Sylvie Courtois
    Nicolas Collongues
    Jérôme de Seze
    Journal of Neurology, 2022, 269 : 3295 - 3300
  • [35] IRIS in a Multiple Sclerosis Patient after Discontinuation of Natalizumab and Newly Started on Fingolimod
    Tomas, Erica
    Wall, Anastacia
    Malik, Amer
    Jung-Henson, Lily
    NEUROLOGY, 2012, 78
  • [36] Alemtuzumab/fingolimod/methylprednisoloneRebound effect in the form of multiple sclerosis relapse and lack of efficacy: case report
    Reactions Weekly, 2024, 2024 (1) : 26 - 26
  • [37] Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
    Boremalm, M.
    Juto, A.
    Axelsson, M.
    Novakova, L.
    Frisell, T.
    Svenningsson, A.
    Lycke, J.
    Piehl, F.
    Selzer, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (08) : 1060 - 1067
  • [38] Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis
    Kalincik, T.
    Jokubaitis, V.
    Spelman, T.
    Horakova, D.
    Havrdova, E.
    Trojano, M.
    Lechner-Scott, J.
    Lugaresi, A.
    Prat, A.
    Girard, M.
    Duquette, P.
    Grammond, P.
    Solaro, C.
    Grand'Maison, F.
    Hupperts, R.
    Prevost, J.
    Sola, P.
    Ferraro, D.
    Terzi, M.
    Butler, E.
    Slee, M.
    Kermode, A.
    Fabis-Pedrini, M.
    McCombe, P.
    Barnett, M.
    Shaw, C.
    Hodgkinson, S.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 596 - 597
  • [39] Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
    Kalincik, Tomas
    Jokubaitis, Vilija
    Spelman, Tim
    Horakova, Dana
    Havrdova, Eva
    Trojano, Maria
    Lechner-Scott, Jeannette
    Lugaresi, Alessandra
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Grammond, Pierre
    Solaro, Claudio
    Grand'Maison, Francois
    Hupperts, Raymond
    Prevost, Julie
    Sola, Patrizia
    Ferraro, Diana
    Terzi, Murat
    Butler, Ernest
    Slee, Mark
    Kermode, Allan
    Fabis-Pedrini, Marzena
    McCombe, Pamela
    Barnett, Michael
    Shaw, Cameron
    Hodgkinson, Suzanne
    Butzkueven, Helmut
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1617 - 1626
  • [40] Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis
    Gunduz, Tuncay
    Kurtuncu, Murat
    Eraksoy, Mefkure
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 11 : 1 - 3
12345